Key result
The inclusion of immunogenic neuraminidase in future influenza virus vaccines is supported by evidence showing it can lessen disease severity, reduce viral shedding, and prevent viral spread.
Why the study?
There has been a concerted effort to investigate incorporating immunogenic forms of influenza virus neuraminidase as a vaccine antigen in future vaccine formulations.
This review highlights the potential of incorporating immunogenic forms of neuraminidase into future influenza vaccines to broaden protection.
Anti-NA immunity merits human vaccine trials; leaves open clinical translation from animal data.
The influenza virus neuraminidase (NA) is primarily involved in the release of progeny viruses from infected cells-a critical role for virus replication. Compared to the immuno-dominant hemagglutinin, there are fewer NA subtypes, and NA experiences a slower rate of antigenic drift and reduced immune selection pressure. Furthermore, NA inhibiting antibodies prevent viral egress, thus preventing viral spread. Anti-NA immunity can lessen disease severity, reduce viral shedding, and decrease viral lung titers in humans and various animal models. As a result, there has been a concerted effort to investigate the possibilities of incorporating immunogenic forms of NA as a vaccine antigen in future vaccine formulations. In this review, we discuss NA-based immunity and describe several human NA-specific monoclonal antibodies (mAbs) that have a broad range of protection. We also review vaccine platforms that are investigating NA antigens in pre-clinical models and their potential use for next-generation influenza virus vaccines. The evidence presented here supports the inclusion of immunogenic NA in future influenza virus vaccines.
No takes yet. Share an insight, caveat, or question.
Rajendran et al. (2021) conducted a review in Influenza virus infection. Neuraminidase (NA) antigens was evaluated. The inclusion of immunogenic neuraminidase in future influenza virus vaccines is supported by evidence showing it can lessen disease severity, reduce viral shedding, and prevent viral spread.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: